In this issue:
Infection rates do not differ among SLE drugs
Which patients are likely to develop more typical RA?
Epratuzumab ineffective in moderateto- severe SLE
. . . anifrolumab looks more promising
Long-term tocilizumab monotherapy:good efficacy and safety
Autoimmune disease + herpes zoster increases stroke risk
Predicting a severe disease course in JIA
Faecal calprotectin predicts IBD in ankylosing spondylitis
Opioids: not cost-effective in OA without comorbidities
NSAIDs versus placebo for spinal pain
Exposure to anti-TNFs and incidence, severity of MI in RA
Please login below to download this issue (PDF)